Olivier Cheneval

Olivier Cheneval

Auto-generated profile, based on publicly available information

Olivier Cheneval

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2016 in Nature
Verified
Journal Article
Open access
PDF file
GBGaurav Bhardwaj
Gaurav Bhardwaj
VMVikram Khipple Mulligan
Vikram Khipple Mulligan
CBChristopher D. Bahl
Christopher D. Bahl
JGJason M. Gilmore
Jason M. Gilmore
PHPeta Harvey
Peta Harvey
DBDavid Baker
David Baker
Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks generally have shapes that have evolved to fit precisely into binding pockets on their targets. Such peptides can have excellent pharmaceutical properties, combining the stability and tissue penetration of small-molecule drugs with the specificity of much larger protein therapeutics. The ability to design constrained peptides with precisely specified tertiary structures would enable the design of shape-complementary inhibitors of arbitrary targets. Here we describe the development of computational methods for accurate de novo design of conformationally restricted peptides, and the use of these methods to design 18–47 residue, disulfide-crosslinked peptides, a subset of which are heterochiral and/or N–C backbone-cyclized. Both genetically encodable and non-canonical peptides are exceptionally stable to thermal and chemical denaturation, and 12 experimentally determined X-ray and NMR structures are nearly identical to the computational design models. The computational design methods and stable scaffolds presented here provide the basis for development of a new generation of peptide-based drugs.

11 June 2014 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
OCOlivier Cheneval
Olivier Cheneval
Christina I SchroederChristina I Schroeder
Christina I Schroeder
Thomas DurekThomas Durek
Thomas Durek
PWPhillip Walsh
Phillip Walsh
YHYen-Hua Huang
Yen-Hua Huang
DCDavid Craik
David Craik

1 January 2008 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SWSimon C. Wagstaff
Simon C. Wagstaff
PFPhilippe Favreau
Philippe Favreau
OCOlivier Cheneval
Olivier Cheneval
GLGavin D. Laing
Gavin D. Laing
MWMark Wilkinson
Mark Wilkinson
RHRobert A. Harrison
Robert A. Harrison

1 May 2006 in Toxicon
Verified
Journal Article
Closed access
PFPhilippe Favreau
Philippe Favreau
LMLaure Menin
Laure Menin
SMSophie Michalet
Sophie Michalet
FPFréderic Perret
Fréderic Perret
OCOlivier Cheneval
Olivier Cheneval
RSReto Stöcklin
Reto Stöcklin

12 April 2013 in ACS Chemical Biology
Verified
Journal Article
Closed access
JGJennifer A. Getz
Jennifer A. Getz
OCOlivier Cheneval
Olivier Cheneval
DCDavid Craik
David Craik
PDPatrick S. Daugherty
Patrick S. Daugherty

1 February 2014 in Chemistry & Biology
Verified
Journal Article
Closed access
Christina I SchroederChristina I Schroeder
Christina I Schroeder
JSJoakim E. Swedberg
Joakim E. Swedberg
JWJane M. Withka
Jane M. Withka
K. Johan RosengrenK. Johan Rosengren
K. Johan Rosengren
MAMuharrem Akcan
Muharrem Akcan
DCDavid Craik
David Craik